Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women

被引:137
作者
Maruyama, Naomi
Miyoshi, Yasuo
Taguchi, Tetsuya
Tamaki, Yasuhiro
Monden, Morito
Noguchi, Shinzaburo
机构
[1] Osaka Univ, Grad Sch Med, Dept Breast & Endocrine Surg, Suita, Osaka 5650871, Japan
[2] Osaka Univ, Grad Sch Med, Dept Surg & Clin Oncol, Suita, Osaka 5650871, Japan
关键词
D O I
10.1158/1078-0432.CCR-06-0267
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Somatic mutations of PIK3CA, which encodes the p110 alpha catalytic subunit of phosphatidylinositol 3-kinase, have recently been shown to play an important role in the pathogenesis and progression of human breast cancers. In this study, the frequency of PIK3CA mutations and their relationship with clinicopathologic and biological variables were investigated in Japanese breast cancers. Experimental Design: Mutational analysis of PIK3CA was done in 188 primary breast cancers of Japanese women. Relationship of these mutations with various clinicopathologic variables [histologic type, tumor size, histologic grade, lymph node status, estrogen receptor (ER)-alpha and progesterone receptor status, and prognosis], biological variables [phospho-AKT (pAKT) and HER2 expression determined by immunohistochemistry], and p53 mutation status was studied. Results: Missense mutations of PIK3CA were found in 44 of 158 invasive ductal carcinomas, 4 of 10 invasive lobular carcinomas, 1 of 4 mucinous carcinomas, 2 of 2 squamous carcinomas, and 2 of 2 apocrine carcinomas, but no mutation was found in 12 noninvasive ductal carcinomas. PIK3CA-mutated tumors were found to be more likely to be ER-alpha positive (P < 0.05) and pAKT positive (P < 0.05). There was no significant association between PIK3CA mutations and p53 mutation status. PIK3CA mutations were significantly (P < 0.05) associated with a favorable prognosis, and multivariate analysis showed that PIK3CA mutation status was a significant (P < 0.05) prognostic factor independent of the other conventional prognostic factors. Conclusions: The frequency of PIK3CA mutations in Japanese breast cancers is similar to that of Caucasian breast cancers. Association of PIK3CA mutations with positive pAKT and positive ER-alpha suggests that PIK3CA mutations might exert their effects through activation of the phosphatidylinositol 3-kinase/AKT/ER-alpha pathway. PIK3CA mutations seem to have a potential to be used as an indicator of favorable prognosis.
引用
收藏
页码:408 / 414
页数:7
相关论文
共 40 条
[1]   The PIK3CA gene is mutated with high frequency in human breast cancers [J].
Bachman, KE ;
Argani, P ;
Samuels, Y ;
Silliman, N ;
Ptak, J ;
Szabo, S ;
Konishi, H ;
Karakas, B ;
Blair, BG ;
Lin, C ;
Peters, BA ;
Velculescu, VE ;
Park, BH .
CANCER BIOLOGY & THERAPY, 2004, 3 (08) :772-775
[2]   MOLECULAR ALTERATIONS OF THE AKT2 ONCOGENE IN OVARIAN AND BREAST CARCINOMAS [J].
BELLACOSA, A ;
DEFEO, D ;
GODWIN, AK ;
BELL, DW ;
CHENG, JQ ;
ALTOMARE, DA ;
WAN, MH ;
DUBEAU, L ;
SCAMBIA, G ;
MASCIULLO, V ;
FERRANDINA, G ;
PANICI, PB ;
MANCUSO, S ;
NERI, G ;
TESTA, JR .
INTERNATIONAL JOURNAL OF CANCER, 1995, 64 (04) :280-285
[3]   Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas [J].
Broderick, DK ;
Di, CH ;
Parrett, TJ ;
Samuels, YR ;
Cummins, JM ;
McLendon, RE ;
Fults, DW ;
Velculescu, VE ;
Bigner, DD ;
Yan, H .
CANCER RESEARCH, 2004, 64 (15) :5048-5050
[4]   PIK3CA mutation and histological type in breast carcinoma:: high frequency of mutations in lobular carcinoma [J].
Buttitta, F ;
Felicioni, L ;
Barassi, F ;
Martella, C ;
Paolizzi, D ;
Fresu, G ;
Salvatore, S ;
Cuccurullo, F ;
Mezzetti, A ;
Campani, D ;
Marchetti, A .
JOURNAL OF PATHOLOGY, 2006, 208 (03) :350-355
[5]   Mutation of the PIK3CA gene in ovarian and breast cancer [J].
Campbell, IG ;
Russell, SE ;
Choong, DYH ;
Montgomery, KG ;
Ciavarella, ML ;
Hooi, CSF ;
Cristiano, BE ;
Pearson, RB ;
Phillips, WA .
CANCER RESEARCH, 2004, 64 (21) :7678-7681
[6]   Amplification of AKT2 in human pancreatic cancer cells and inhibition of ATK2 expression and tumorigenicity by antisense RNA [J].
Cheng, JQ ;
Ruggeri, B ;
Klein, WM ;
Sonoda, G ;
Altomare, DA ;
Watson, DK ;
Testa, JR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (08) :3636-3641
[7]   Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage [J].
David, O ;
Jett, J ;
LeBeau, H ;
Dy, G ;
Hughes, J ;
Friedman, M ;
Brody, AR .
CLINICAL CANCER RESEARCH, 2004, 10 (20) :6865-6871
[8]   Pleomorphic lobular carcinoma of the breast: its cell kinetics, expression of oncogenes and tumour suppressor genes compared with invasive ductal carcinomas and classical infiltrating lobular carcinomas [J].
Frolik, D ;
Caduff, R ;
Varga, Z .
HISTOPATHOLOGY, 2001, 39 (05) :503-513
[9]   Meeting highlights:: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005 [J].
Goldhirsch, A ;
Glick, JH ;
Gelber, RD ;
Coates, AS ;
Thürlimann, B ;
Senn, H ;
Albain, KS ;
Bergh, J ;
Castiglione-Gertsch, M ;
Coates, AS ;
Costa, A ;
Cuzick, J ;
Davidson, N ;
Forbes, JF ;
Gelber, RD ;
Goss, P ;
Harris, J ;
Glick, JH ;
Goldhirsch, A ;
Howell, A ;
Ingle, JN ;
Jakesz, R ;
Jassem, J ;
Kaufmann, M ;
Martin, M ;
Mauriac, L ;
Morrow, M ;
Mouridsen, HT ;
Namer, M ;
Piccart-Gebhart, MJ ;
Possinger, K ;
Pritchard, K ;
Rutgers, EJT ;
Thürlimann, B ;
Viale, G ;
Wallgren, A ;
Wood, WC .
ANNALS OF ONCOLOGY, 2005, 16 (10) :1569-1583
[10]  
Grille SJ, 2003, CANCER RES, V63, P2172